Cell Gene Therapy Cdmo Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The global cell and gene therapy CDMO market encompasses service providers that offer end-to-end support for the development and commercial-scale manufacturing of cell-based and gene-based therapies. These services include process development, cell line development, viral vector manufacturing, and fill-finish operations tailored to the unique requirements of living cell products. The market is positioned at the intersection of advanced therapeutics and contract manufacturing, serving as a critical enabler for biotech companies that lack in-house manufacturing capabilities. With the market valued at approximately $4.0 billion in 2025, it represents a significant and rapidly expanding segment within the broader biopharmaceutical CDMO industry.

• •Provides integrated development and manufacturing services for cell and gene therapies including viral vectors, plasmids, and cell-based products
• •Market valued at approximately $4.0 billion in 2025 with projections to reach between $74 billion and $125 billion by 2034-2035 depending on the source
• •Services span process development, clinical and commercial manufacturing, and regulatory support across all phases of therapy development

The market is propelled by the surging pipeline of cell and gene therapy candidates, with hundreds of clinical trials ongoing globally for treatments targeting cancer, rare diseases, and genetic disorders. The complexity and personalized nature of these therapies make in-house manufacturing challenging, driving demand for specialized CDMO expertise. Regulatory approvals of novel cell and gene therapies have accelerated, creating immediate need for commercial-scale manufacturing capacity that many developers cannot build independently. Additionally, the trend toward personalized medicine and autologous therapies requiring individualized manufacturing processes has amplified the need for flexible, scalable CDMO partnerships.

• •Rising number of FDA and EMA-approved cell and gene therapies creating commercial manufacturing demand
• •High barriers to entry due to specialized infrastructure requirements for viral vector and cell processing
• •Increasing adoption of outsourcing by large pharmaceutical companies entering the cell and gene therapy space

The market can be segmented by therapy type, including cell therapy (such as CAR-T and stem cell treatments) and gene therapy (including viral vector-based and non-viral approaches), as well as by service type covering process development, manufacturing, and analytical services. Geographically, North America currently dominates the market due to the concentration of biotechnology companies, favorable regulatory environments, and significant R&D investment. The Asia-Pacific region is emerging as a fast-growing market segment, driven by cost advantages, improving regulatory frameworks, and increasing clinical trial activity. Europe maintains a strong presence, particularly in academic and research-driven cell therapy development.

• •Cell therapy segment currently represents the largest share, though gene therapy services are growing at a faster pace
• •North America accounts for the majority of market share, followed by Europe and the rapidly expanding Asia-Pacific region
• •Manufacturing services constitute the largest revenue segment, with process development growing as pipelines mature

What are the recent trends and outlook?

The market is witnessing significant capacity expansion as CDMOs invest in new manufacturing facilities to meet anticipated demand from approved therapies moving into commercial production. Single-use technologies and modular manufacturing approaches are gaining traction to improve flexibility and reduce contamination risks in cell processing. Integration of artificial intelligence and automation in manufacturing processes is emerging as a differentiator for CDMOs seeking to improve efficiency and consistency in complex cell culture operations. The future outlook remains highly positive, with the market expected to maintain robust growth as more cell and gene therapies achieve regulatory approval and manufacturers seek to de-risk capacity constraints through strategic partnerships with specialized CDMOs.

• •CDMOs are investing heavily in new manufacturing capacity, particularly for viral vector production which remains a bottleneck
• •Allogeneic and off-the-shelf cell therapies are driving demand for standardized, high-volume manufacturing capabilities
• •Strategic partnerships and long-term supply agreements between biotech developers and CDMOs are becoming increasingly common to secure manufacturing capacity